Airing weekdays at 7:30 A.M. on

Airing weekdays at 7:30 A.M. on

We’re going Behind the Mystery of two rare diseases: Castleman disease and chondrosarcoma.

There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades. Inhibrx, a clinical-stage biotechnology company, is dedicated to helping people with life-threatening conditions. They are developing a therapeutic option for chondrosarcoma called INBRX-109, which is currently in clinical trials.

Then, meet with physician, scientist, patient, and best-selling author of Chasing My Cure David Fajgenbaum to learn more about Castleman Disease. Plus, one patient’s journey from facing his own mortality to finding hope through advocacy.

Health, Wealth, Beauty, and Business

Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]

iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.

There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.

Comments

comments